BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Alliance for SoCal Innovation - ECPv6.15.20//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:Alliance for SoCal Innovation X-ORIGINAL-URL:https://alliancesocal.org X-WR-CALDESC:Events for Alliance for SoCal Innovation REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:America/Los_Angeles BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20250309T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20251102T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20260308T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20261101T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20270314T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20271107T090000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260521T133000 DTEND;TZID=America/Los_Angeles:20260521T153000 DTSTAMP:20260608T010923 CREATED:20260427T220324Z LAST-MODIFIED:20260521T155047Z UID:6564-1779370200-1779377400@alliancesocal.org SUMMARY:First Look SoCal Bioscience Innovation Showcase at UCLA's LABEST 2026 DESCRIPTION:The First Look SoCal Innovation Showcase Series celebrates the best early-stage startups commercializing deep tech\, bioscience\, and medtech breakthroughs emerging from the top universities and research institutions in Southern California. \n\n\n\nFor the second year in a row\, we are partnering with UCLA to host the First Look SoCal Bioscience Showcase at the LABEST conference which features two full days of world-class life science conferences at the Luskin Conference Center on the UCLA campus. \n\n\n\nLABEST attracts over 1\,500 life science industry professionals from leading corporations\, VCs\, and research institutions around the world. Plus there are workshops and panels for early stage founders and much\, much more. \n\n\n\nEach startup selected for the First Look SoCal Bioscience Showcase on Thursday May 21 will present a 3-minute quick pitch followed by 9 minutes of Q&A led by a panel of leading investors\, corporates\, and subject matter experts who will provide invaluable insights and access to capital. Celebrate and connect with industry leaders and investors at the post-event networking reception. \n\n\n\nThe showcase will be held from 1:30-3:30 PM in the “Illumination Room” on the second floor of the Luskin Conference Center. \n\n\n\nCheck out the LABEST website for attendee info\, agenda\, and registration: \n\n\n\n\nAgenda + Registration\n\n\n\n\n\n\n\n\n \n \n \n \n Our sponsors empower us to showcase early stage innovators\n \n \n \n Thank you to our generous sponsors who underwrite the First Look SoCal Innovation Showcase. Their leadership is the key to ensuring that early stage innovation leaps from the lab to impact. \n \n \n \n \n \n \n \n \n \n Lead Sponsor\n \n\n \n \n \n KPPB\, LP\n \n \n \n Website\n\n |\n LinkedIn\n\n \n \n \n \n KPPB is committed to protecting risk-takers and their ideas. Our attorneys are motivated by a desire to see transformative technologies succeed. We are proud to be trusted advisors who are respected for our technical expertise. \n \n \n \n \n\n \n \n Additional Sponsors \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\nBioscience Startups Presenting\n\n\n\n\n\n\n\n\n\n\n\nBioscience Expert Panel\n\n\n\n\n \n \n \n \n \n Charles Thomas\n Partner\n KPPB\, LP\n View Bio \n \n \n \n \n \n \n \n \n \n \n Charles Thomas\n Partner\n KPPB\, LP\n \n \n \n \n \n \n \n \n \n \n Charles’s expertise in biotechnology\, medicine\, and biochemistry extends from his years of experience in both industry and academia. As a research associate at a biotech company\, he was integral to the development of vector-based therapeutics for ocular diseases and vaccines for malaria. In his graduate work\, Charles appropriated molecular biology and embryonic cell culture techniques to elucidate mechanisms of intrinsic neuroinflammation in the rare pediatric disorder Aicardi-Goutières Syndrome.  His work led to a discovery of several FDA-approved medications that could be repurposed to treat affected patients. Throughout the years\, Charles’s research has been published in a number of top-tier journals\, including Cell Stem Cell\, Annual Review of Cell and Developmental Biology\, Journal of Virology\, and Molecular Therapy. \nCharles has established a practice that focuses on prosecution of emerging technologies in the various fields of biology and chemistry\, including therapeutic discovery\, immunology\, cytometry\, cell culture\, molecular biology\, bioinformatics\, recombinant biology\, and small molecule chemistry. Through detailed communications and diligent effort\, Charles strives to provide the most robust patent protection for his clients. \nPRACTICE AREAS\nPatent Protection \nEDUCATION\nVirginia Tech\, B.S.\, Biochemistry; B.S.\, Biology; B.A.\, Chemistry\, summa cum laude\nUniversity of California\, San Diego\, Ph.D.\, Biomedical Sciences\nUniversity of Southern California\, Gould School of Law\, J.D. \nBAR ADMISSIONS\nCalifornia State Bar\nUnited States Patent and Trademark Office \n \n \n \n \n \n \n \n \n \n Duncan Huston-Paterson\n Director\, Business Development – Early Innovation\n Amgen\n View Bio \n \n \n \n \n \n \n \n \n \n \n Duncan Huston-Paterson\n Director\, Business Development – Early Innovation\n Amgen\n \n \n \n \n \n \n \n \n \n \n Duncan Huston-Paterson is a member of the Technology Business Development group. Duncan focuses on scouting and deal-making to access innovative technologies and platforms that enable the next generation of therapeutics at Amgen. Prior to joining Amgen in 2020\, Duncan spent 4 years at Integral Molecular where he led a team that developed\, launched\, and commercialized a novel target discovery platform\, resulting in multiple partnerships with large Pharma. Duncan grew up in South Africa and completed his early scientific training at University of Pretoria\, before going on to receive his DPhil at Oxford University in the UK\, where he studied the biochemical determinants of bird flu transmission to humans. \n \n \n \n \n \n \n \n \n \n Sonia Maryam Setayesh\n Partner\n Civilization Ventures\n View Bio \n \n \n \n \n \n \n \n \n \n \n Sonia Maryam Setayesh\n Partner\n Civilization Ventures\n \n \n \n \n \n \n \n \n \n \n Sonia is an Investment Partner at Civilization Ventures\, leading scientific diligence on early-stage biotech companies. She earned her PhD at USC\, where she developed liquid-biopsy assays—including an early breast-cancer test in collaboration with clinical sites—and previously helped advance two targeted immunotherapies into clinical trials. Sonia also brings hands-on oncology BD experience and has served as VP of Nucleate HQ and Biotech Connection Los Angeles. \n \n \n \n \n \n \n \n \n \n Chris Bostick\n Partner\n OCV Partners\n View Bio \n \n \n \n \n \n \n \n \n \n \n Chris Bostick\n Partner\n OCV Partners\n \n \n \n \n \n \n \n \n \n \n \n\nChris is passionate about technologies using interdisciplinary approaches to enable precision medicine. He focuses on healthcare investments at OCV and Co-led investments including Rad AI and TORL Biotherapeutics. Most recently he was selected to the Milken Institute Young Leaders Circle in 2024 and has been recognized by Biocom in 2021 as one of ten life science trailblazers under 40. Prior to OCV\, Dr. Bostick completed postdoctoral work at the Institute for Genomic Medicine at Columbia University where he researched precision medicine-based approaches for treating genetic neurological disorders. Prior to that\, he researched drug metabolism\, bioelectronics/biosensors\, and nanotechnology for his Ph.D. Dr. Bostick holds a B.S. in Biology with a minor in Business from Cornell University and a Ph.D. in Pharmacological and Pharmaceutical Sciences from West Virginia University where he was an NSF IGERT Fellow. \n\n\n \n \n \n \n \n \n\n\n\nBioscience Startup Presenters\n\n\n\n\n \n \n \n \n \n Wael El-Nachef\n Founder + CEO\n Angel City Bio – Vesudra\n View Bio \n \n \n \n \n \n \n \n \n \n \n Wael El-Nachef\n Founder + CEO\n Angel City Bio – Vesudra\n \n \n \n \n \n \n \n \n \n \n Dr. El-Nachef is a physician-scientist who is a board-certified gastroenterologist with a clinical focus on neurogastroenterology and GI motility disorders. While on faculty at UCLA\, Dr. El-Nachef founded a clinic exclusively dedicated to patients with Parkinson’s disease suffering from gastrointestinal issues. \nDr. El-Nachef completed medical school at Northwestern University and Gastroenterology training at UCLA. He obtained his PhD studying the development and regeneration of the enteric nervous system\, and this work was completed at the California Institute of Technology. \nTying together his unique clinical experience with a basic science perspective\, Dr. El-Nachef strives to serve his patients with compassion to address their symptoms and improve their quality of life. \n \n \n \n \n \n \n \n \n \n Benjamin Tully\n Co-Founder + CEO\n Branchpoint Biosciences\n View Bio \n \n \n \n \n \n \n \n \n \n \n Benjamin Tully\n Co-Founder + CEO\n Branchpoint Biosciences\n \n \n \n \n \n \n \n \n \n \n Dr. Benjamin Tully is the Co-founder and CEO of Branchpoint Biosciences. Holding a Ph.D. in microbial ecology and large-scale genomics\, he brings extensive expertise in bioinformatics\, algorithm design\, and the development of advanced qPCR assays. At Branchpoint Biosciences\, Dr. Tully leads efforts to solve the “quantification bottleneck” facing the microbiome and probiotic industries. By setting rigorous validation standards and building high-precision platforms for microbial quantification – including strain-specific differentiation – he is dedicated to advancing the broader microbial bioeconomy. Dr. Tully actively collaborates with top academic and industry leaders to drive data-driven innovation forward. \n \n \n \n \n \n \n \n \n \n Katie Sicinski\n Co-Founder + CEO\n Censera\n View Bio \n \n \n \n \n \n \n \n \n \n \n Katie Sicinski\n Co-Founder + CEO\n Censera\n \n \n \n \n \n \n \n \n \n \n Katie Sicinski obtained her PhD in Chemistry from Tufts University\, where her dissertation focused on developing novel chemical methods to improve the in vivo stability and delivery of GLP-1 peptides for the treatment of type 2 diabetes\, obesity\, and Alzheimer’s disease. This work resulted in foundational patents that form the basis of Velum\, Inc.\, a Tufts University spinout. Following her PhD\, she joined PepGen\, Inc.\, a Cambridge\, MA-based startup\, where she helped establish discovery chemistry operations and develop antisense medicines for rare neuromuscular diseases. Katie then received an NIH Ruth L. Kirschstein National Research Service Award (NRSA) postdoctoral fellowship to study protein engineering at Caltech in the lab of Nobel laureate Prof. Frances Arnold\, where she met her co-founder Dr. Casey Ritts. Together\, they are combining their expertise in organic chemistry\, protein engineering\, oligonucleotide synthesis\, and in vivo translational research to build Censera\, a therapeutics company focused on improving the delivery of antisense medicines to the brain. \n \n \n \n \n \n \n \n \n \n Zipeng Zeng\n Co-Founder + CEO\n DeepNephro Inc\n View Bio \n \n \n \n \n \n \n \n \n \n \n Zipeng Zeng\n Co-Founder + CEO\n DeepNephro Inc\n \n \n \n \n \n \n \n \n \n \n Zipeng Zeng\, PhD\, is the Co-founder and CEO of DeepNephro\, Inc.\, a biotechnology startup developing next-generation human kidney organoid platforms for disease modeling\, drug discovery\, and nephrotoxicity assessment. He received his PhD in Development\, Stem Cells and Regenerative Medicine from the Keck School of Medicine at the University of Southern California\, where his research focused on kidney progenitor cell differentiation and expansion\, kidney regeneration\, and kidney organoid engineering.  \nPrior to founding DeepNephro\, Zipeng worked in Business Development & Licensing at Biocytogen\, focusing on strategic partnerships and technology licensing in the biotechnology and therapeutics space. He also previously interned at Flagship Pioneering and Wavemaker Three-Sixty Health\, and was a co-founder of the Nucleate Los Angeles chapter\, supporting the next generation of biotech entrepreneurs. \n \n \n \n \n \n \n \n \n \n Adam Klie\n Head of Technology\n Gaius Therapeutics\n View Bio \n \n \n \n \n \n \n \n \n \n \n Adam Klie\n Head of Technology\n Gaius Therapeutics\n \n \n \n \n \n \n \n \n \n \n Dr. Adam Klie is Head of Technology at Gaius Therapeutics\, where he leads the artificial intelligence and machine learning (AI/ML) platform for discovery and design of cell type-specific genetic switches for in vivo CAR-Treg therapies. He earned his B.S. in Bioengineering and Ph.D. in Bioinformatics and Systems Biology from UCSD under the guidance of Dr. Hannah Carter\, a global leader in computational immuno-oncology. His thesis developed AI/ML methods for decoding the cell type-specific regulatory genome. During his Ph.D.\, he was also a visiting scholar in the lab of Professor Anshul Kundaje at Stanford\, a global pioneer in applying AI/MLto gene regulation. He went on to become an Eric and Wendy Schmidt AI in Science Fellow. His work brings together AI/ML and regulatory genomics to enable the next generation of precision cell therapies. \n \n \n \n \n \n \n \n \n \n Hairuo Guo\n Co-Founder + CEO\n Holomorph\n View Bio \n \n \n \n \n \n \n \n \n \n \n Hairuo Guo\n Co-Founder + CEO\n Holomorph\n \n \n \n \n \n \n \n \n \n \n Hairuo is a machine learning expert with experience at the intersection of AI\, aerospace\, and scientific discovery. He is leaving a position as an engineering manager in the Data Science and AI Department at The Aerospace Corporation\, where he served as a primary researcher on AI methods for early wildfire detection and as a tech lead for an internal LLM-powered RAG application. His earlier work includes anomaly detection on rocket launch telemetry\, machine learning for orbital rendezvous with non-cooperative targets time\, and time at Meta as a data scientist. Holomorph\, his team\, was a finalist and Demo Day golden ticket winner in the 2025-2026 Nucleate Los Angeles Activator program. He holds an M.Eng. and S.B. in Computer Science and Engineering\, along with an S.B. in Comparative Media Studies\, all from MIT. \n \n \n \n \n \n \n \n \n \n Konstantin Kazarian\n Co-Founder + CEO\n Hybrid Biotherapeutics\n View Bio \n \n \n \n \n \n \n \n \n \n \n Konstantin Kazarian\n Co-Founder + CEO\n Hybrid Biotherapeutics\n \n \n \n \n \n \n \n \n \n \n Dr. Kazarian is an experienced biotech leader with a background in protein biochemistry and structural biology. After postdoctoral training\, he transitioned into industry\, holding roles from project management to VP-level leadership across leading CDMOs including Oxford Biomedica\, Northway Biotech\, Rentschler Biopharma\, and Pyramid Pharma Services. He brings extensive experience in CMC strategy\, manufacturing scale-up\, partnerships\, and early-stage company building. \n \n \n \n \n \n \n \n \n \n Samuel Lobo\n Chief Scientific Officer\n ProFoldBio\n View Bio \n \n \n \n \n \n \n \n \n \n \n Samuel Lobo\n Chief Scientific Officer\n ProFoldBio\n \n \n \n \n \n \n \n \n \n \n Samuel Lobo is co-founder and Chief Scientific Officer of ProFoldBio\, a UCSB spinout developing amyloid-targeting diagnostics and therapeutics. He recently completed his PhD in Chemical Engineering at UCSB\, where he developed biophysical and AI methods to study amyloid formation. \n \n \n \n \n \n \n \n \n \n Chao Peng\n Co-Founder + CEO\n ProteoSolve\n View Bio \n \n \n \n \n \n \n \n \n \n \n Chao Peng\n Co-Founder + CEO\n ProteoSolve\n \n \n \n \n \n \n \n \n \n \n Dr. Chao Peng is an assistant professor at UCLA. He has more than 13 years experiment in\nAlzheimer’s disease. Focusing on Alzheimer’s disease mechanism study and drug development. He has built various novel disease models for Alzheimer’s disease drug development. \n \n \n \n \n \n \n \n \n \n Casey Ritts\n Co-Founder + CSO\n Censera\n View Bio \n \n \n \n \n \n \n \n \n \n \n Casey Ritts\n Co-Founder + CSO\n Censera\n \n \n \n \n \n \n \n \n \n \n Dr. Casey Ritts earned his degree (BS) in biochemistry from University of Wisconsin–Madison and his PhD in chemistry from University of Minnesota–Twin Cities. He is an expert synthetic chemist whose thesis was based in mechanism-driven methodology development and natural product total synthesis. Following his doctoral studies\, Casey earned a prestigious American Cancer Society (ACS) Postdoctoral Fellowship to immerse himself in protein engineering at Caltech under the advisement of Prof. Frances Arnold—the 2018 Nobel laureate in chemistry for inventing directed evolution. He was additionally made a member of the ACS/Lisa Dean Moseley Foundation Cancer Stem Cell Consortium that focuses on translational medicines that target cancer resistance and recurrence. Motivated to make an impact on patient health\, Casey has worked at the interface of protein engineering and organic synthesis (alongside his co-founder\, Katie Sicinski) to invent innovative technology for antisense medicine. He and Katie will be the devoted co-founders of their start-up\, Censera. \n \n \n \n \n \n \n \n \n \n Theodosia Bartashevitch\n Co-Founder + CSO\n Holomorph\n View Bio \n \n \n \n \n \n \n \n \n \n \n Theodosia Bartashevitch\n Co-Founder + CSO\n Holomorph\n \n \n \n \n \n \n \n \n \n \n \n\n\n\n\n\nTheodosia is a computational structural biologist and scientific programmer developing Amylnac\, a program that produces almanacs of known and predicted amyloid structures\, including precursors to disease-associated folds\, alongside other biophysical algorithms for anti-neurodegeneration drug discovery. She will receive her PhD this summer in Biochemistry\, Molecular\, and Structural Biology from UCLA\, where she developed novel algorithms for comprehensive amyloid folding landscape generation and built an end-to-end prototype of Amylnac. She is the inventor on two provisional patents filed on the work. Holomorph\, her team\, was a finalist and Demo Day golden ticket winner in the 2025-2026 Nucleate Los Angeles Activator program. She holds a BA in Biochemistry and Molecular Biology from Reed College.\n\n\n\n\n\n\n\n \n \n \n \n \n \n\n\n\nLook Forward To…\n\n\n\nConnect with investors\, peers\, and mentors\n\n\n\nUnparalleled opportunities to connect with investors\, mentors and other support resources crucial for early stage startups. \n\n\n\nStartup quick-pitch presentations\n\n\n\nEach selected started will distill their scientific breakthroughs and market opportunitiy into 3-minute quick pitch presentation followed by 9 minutes of moderated Q&A led by a panel of investors\, corporate leaders\, and subject matter experts. \n\n\n\nNetworking Reception\n\n\n\nStay for drinks and small bites as we celebrate and connect with attendees and speakers. URL:https://alliancesocal.org/event/first-look-socal-bioscience-2026/ LOCATION:The Luskin Conference Center at UCLA in Los Angeles\, CA\, 425 Westwood Plaza\, Los Angeles\, California\, 90095\, United States CATEGORIES:Alliance Events END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260604T173000 DTEND;TZID=America/Los_Angeles:20260604T200000 DTSTAMP:20260608T010923 CREATED:20260505T032011Z LAST-MODIFIED:20260505T032013Z UID:7316-1780594200-1780603200@alliancesocal.org SUMMARY:Fundraising in Today's Market - DTLA DESCRIPTION:Founder x VC Panel: Navigating Fundraising in Today’s Market \n\n\n\nJoin us for an evening in Downtown Los Angeles as founders and venture capitalists come together for an open conversation on what it really takes to raise capital in today’s environment. This rooftop event is co-produced with Gunderson Dettmer and brings together members of the SoCal startup ecosystem for insights\, connection\, and community. \n\n\n\n🎙️ Panel Discussion:Hear directly from leading venture capitalists and founders as they share perspectives on fundraising\, what investors are looking for today\, and how to position your company for success. \n\n\n\nWhether you’re actively raising\, preparing for your next round\, or simply looking to better understand the venture landscape\, this event is designed to give you practical\, real-world insights. \n\n\n\n🍕 Networking Reception:Connect with fellow founders\, investors\, and operators over drinks and pizza on the rooftop patio. \n\n\n\n📍 Location: DTLA (address upon registration)📅 Date: Thursday\, June 4🕠 Time: 5:30 PM – 8:00 PM \n\n\n\nAgenda: \n\n\n\n5:30 PM: Arrival & Check-in6:00 PM: Welcome & Panel Discussion6:45 PM: Networking Reception8:00 PM: Event Concludes \n\n\n\nThis event is in support of the SoCal Venture Pipeline program from the Alliance for SoCal Innovation which connects investor-ready startups seeking Seed and Series A funding with the right VCs that match their criteria. Learn more at our website. \n\n\n\nThe SoCal Venture Pipeline program is made possible by the generous underwriting of the following sponsors: URL:https://alliancesocal.org/event/fundraising-in-todays-market-dtla/ CATEGORIES:Alliance Events ATTACH;FMTTYPE=image/avif:https://alliancesocal.org/wp-content/uploads/2026/05/fiTM-DTLA-2026.avif ORGANIZER;CN="Alliance for SoCal Innovation":MAILTO:info@alliancesocal.org END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260924T130000 DTEND;TZID=America/Los_Angeles:20260924T183000 DTSTAMP:20260608T010923 CREATED:20260528T002740Z LAST-MODIFIED:20260528T002742Z UID:7387-1790254800-1790274600@alliancesocal.org SUMMARY:The SoCal Deep Tech Symposium 2026 DESCRIPTION:Featuring the First Look SoCal Deep Tech Innovation Showcase\n\n\n\n\n\nConnect with Deep Tech innovators and investors at the 3nd Annual SoCal Deep Tech Symposium in El Segundo. Sponsored by KPPB.\n\n\n\nWhat to know:  The Deep Tech Symposium gathers over 130 top corporate leaders\, government representatives\, startup founders\, and early-stage investors in fields such as Aerospace & Defense\, Advanced Manufacturing & Robotics\, Autonomous Mobility\, Renewable Energy\, AI and more. \n\n\n\nGet a glimpse of the future and what’s getting funded today: See startup founders quick pitch then respond to in-depth Q&A from a panel of investors and subject matter experts. We begin with The First Look SoCal Deep Tech Innovation Showcase which features very early stage startups commercializing IP created at top research universities throughout Southern California. This is your opportunity to get a glimpse of tomorrow’s tech before it hits the market. The second showcase will feature early stage Deep Tech startups from the region’s top accelerator programs seeking Seed and Series A funding. \n\n\n\nSponsors & Partners\n\n\n\n\n \n \n \n \n First Look SoCal Showcase – Lead Sponsor \n \n \n \n \n \n \n Host Partner \n \n \n \n \n\n\n\n\n\nTHE 2026 AGENDA: \n\n\n\n​PRE-EVENT WORKSHOP FOR FOUNDERS (separate ticket required) \n\n\n\n​11AM – 1PM: Workshop with legal and fundraising experts to help startup founders navigate issues such as Protecting and Commercializing Deep Tech Intellectual Property; Fundraising\, and avoiding legal pitfalls. Lunch provided at the workshop. Combination ticket includes workshop\, lunch and General Admission to the symposium plus networking reception. \n\n\n\nGeneral Admission Agenda:\n\n\n\n1:00 PM: Attendee Check-in \n\n\n\n​1:30 PM: Opening remarks \n\n\n\n​1:40 PM: Keynote (TBD) \n\n\n\n​2:00 PM: First Look SoCal Deep Tech Innovation Showcase \n\n\n\nAttendees get an early glimpse (or “first look”) into exciting new scientific advances with high potential for market success and disruption emerging from SoCal’s unparalleled research institutions and universities (UCLA\, Caltech\, USC\, UC Irvine\, UCSD\, UCSB\, UC Riverside SDSU\, CalPoly\, LMU). Connecting these founders with experienced industry leaders who can help them grow and succeed has enormous value in launching these innovations from lab to market. Startups are selected from a pool of applicants sourced directly from the tech transfer offices of the universities. On the stage\, each startup gets 3 minutes to pitch immediately followed by 6 minutes of Q&A with a panel of industry leaders with subject matter expertise.ect matter experts. \n\n\n\n3:15 PM: Break \n\n\n\n3:45 PM: Deep Tech Startup Showcase \n\n\n\nEarly-stage startups raising large Seed or Series Afunding referred from the region’s accelerators and ecosystem support organizations (Starburst\, Techstars\, LACI\, etc.) will have the opportunity to pitch for 3 minutes followed by 6 minutes of Q&A led by investors\, strategics and other subject matter experts. The interaction between the founders and expert panelists will reveal unique insights about fundraising and the startup journey that are rarely seen outside of confidential due diligence investigations. \n\n\n\n5:00 PM: Investor Panel (TBD) \n\n\n\n5:30 PM: Networking Reception \n\n\n\n​Continue the conversation and connect while enjoying refreshments and snacks \n\n\n\nThe First Look SoCal Deep Tech Innovation Showcase\n\n\n\n\n\n\n\nEach startup will present a 3-minute quick pitch followed by 6 minutes of Q&A led by a panel of leading investors\, corporates\, and subject matter experts who will provide invaluable insights and access to capital. \n\n\n\nLook Forward To…\n\n\n\nConnect with investors\, peers\, and mentors\n\n\n\nUnparalleled opportunities to connect with investors\, mentors and other support resources crucial for early stage startups. Past years attracted over 300 attendees including over 130 investors such as Lux Capital\, Kairos\, Wavemaker 360\, Upfront\, NEA\, Elevation Ventures\, FullCycle\, Aligned Climate Capital\, Mitsubishi Ventures and many more.  \n\n\n\nStartup quick-pitch presentations\n\n\n\nSee selected Deep Tech (Robotics\, Aerospace\, Advanced Manufacturing\, Energy\, Materials) startups doing 3-minute quick pitch presentations followed by 6 minutes of moderated Q&A led by a panel of investors\, corporate leaders\, and subject matter experts. \n\n\n\nTop university-based deep tech startups\n\n\n\nThis is SoCal’s premiere gathering of the best startups emerging from the region’s top research institutions so it attracts the region’s community in a rare concentrated program that celebrates the entrepreneur’s journey from lab to market. \n\n\n\nWorkshop for startup founders\n\n\n\nLearn from subject matter experts in IP law and licensing best practices for protecting and monetizing intellectual property as well as early stage startup commercialization of deep tech innovations. \n\n\n\nNetworking Reception\n\n\n\nStay for drinks and small bites as we celebrate and connect with attendees and speakers. URL:https://alliancesocal.org/event/the-socal-deep-tech-symposium-2026/ CATEGORIES:Alliance Events END:VEVENT END:VCALENDAR